Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction
- 1 May 2003
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 284 (5) , H1560-H1569
- https://doi.org/10.1152/ajpheart.01087.2002
Abstract
Premenopausal women are much less prone to develop cardiovascular disease than men of similar age, but this advantage no longer applies after menopause. We previously found that male mice have a significantly higher rate of cardiac rupture than females during the acute phase of myocardial infarction (MI); however, the effects of sexual hormones on chronic remodeling are unknown. We hypothesized that estrogen (E) may protect the heart from chronic remodeling and deterioration of function post-MI, whereas testosterone (T) may have adverse effects. Mice (4 wk old) of both genders were divided into four groups: female groups consisted of 1 ) sham ovariectomy (S-Ovx) + placebo (P) (S-Ovx + P), 2 ) S-Ovx + T, 3 ) Ovx + P, and 4 ) Ovx + T; and male groups consisted of 1 ) sham castration (S-Cas)+ P (S-Cas + P), 2 ) S-Cas + 17β-estradiol (E), 3 ) Cas + P, and 4 ) Cas + E. MI was induced 6 wk later. Echocardiography was performed to assess cardiac function and left ventricular dimensions (LVD). Myocyte cross-sectional area (MCSA) was measured at the end of the study. In females, both testosterone and ovariectomy decreased ejection fraction (EF) and increased LVD, and when combined they aggravated cardiac function and remodeling further. Testosterone significantly increased MCSA. In males, castration or estrogen increased EF and reduced LVD, whereas castration significantly reduced MCSA. Our data suggest that estrogen prevents deterioration of cardiac function and remodeling after MI, but testosterone worsens cardiac dysfunction and remodeling and has a pronounced effect when estrogen levels are reduced.Keywords
This publication has 56 references indexed in Scilit:
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical TrialsThe American Journal of Geriatric Cardiology, 2000
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- The Long-Term Effects of Oral and Transdermal Postmenopausal Hormone Replacement Therapy on Nitric Oxide, Endothelin-1, Prostacyclin, and ThromboxaneFertility and Sterility, 1998
- Effect of High Salt Intake in Mutant Mice Lacking Bradykinin-B 2 ReceptorsHypertension, 1997
- Anabolic Steroid Use as the Possible Precipitant of Dilated CardiomyopathyCardiology, 1997
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal MenNew England Journal of Medicine, 1996
- Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomyJournal of Clinical Endocrinology & Metabolism, 1995
- Effects of Androgens on Coronary Artery Atherosclerosis and Atherosclerosis-Related Impairment of Vascular ResponsivenessArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham populationPublished by Elsevier ,1986